Department of Practice and Policy, Centre for Paediatric Pharmacy Research (CPPR), University College London School of Pharmacy, British Medical Association/Tavistock House, Entrance A, 1st Floor Tavistock Square, London, WC1H 9JP, UK.
Pediatr Nephrol. 2013 Jan;28(1):25-31. doi: 10.1007/s00467-012-2149-1. Epub 2012 Mar 28.
Drug therapies in the management of chronic kidney disease (CKD) are complex and specialised and have a high potential for drug-related problem (DRP). In adult CKD populations, the identification and resolution of DRP has been shown to have beneficial effects on disease management, adherence and knowledge of treatment, patient's quality of life, hospitalisation rate and length of stay and cost to the healthcare system. The focus of this article is the review of published studies on DRP in children with CKD. There is a lack of information on the epidemiology of DRP in this patient group, and research in this area is therefore needed to better understand and manage DRP in children with CKD.
药物治疗在慢性肾脏病（CKD）的管理中非常复杂和专业化，并且具有很高的药物相关问题（DRP）风险。在成人 CKD 患者中，已经证明识别和解决 DRP 对疾病管理、治疗依从性和知识、患者的生活质量、住院率和住院时间以及医疗保健系统的成本都有有益的影响。本文的重点是对发表的关于 CKD 儿童 DRP 的研究进行综述。在这一患者群体中，DRP 的流行病学信息缺乏，因此需要在这一领域进行研究，以更好地理解和管理 CKD 儿童的 DRP。
